SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Giesselman Janet Plaut | Director | 2026-07-31 | Grant/award | 98 | $8K |
| Nayyar Nayaki R | Director | 2026-07-31 | Grant/award | 413 | $32K |
| Policinski Christopher J. | Director | 2026-07-31 | Grant/award | 413 | $32K |
| KISSAM LUTHER C IV | CEO, Crop Protection Business | 2026-06-01 | Grant/award | 24138 | $0 |
| Engel Klaus A | Director | 2026-04-30 | Tax withholding | 906 | $73K |
| Giesselman Janet Plaut | Director | 2026-04-30 | Grant/award | 96 | $8K |
| Lutz Marcos M | Director | 2026-04-30 | Tax withholding | 906 | $73K |
| Nayyar Nayaki R | Director | 2026-04-30 | Grant/award | 401 | $32K |
| EVERITT DAVID C | Director | 2026-04-28 | Grant/award | 2350 | $0 |
| Engel Klaus A | Director | 2026-04-28 | Grant/award | 2350 | $0 |
| Giesselman Janet Plaut | Director | 2026-04-28 | Grant/award | 2350 | $0 |
| Gilson Jean-Marc | Director | 2026-04-28 | Grant/award | 2350 | $0 |
| Grimes Karen H. | Director | 2026-04-28 | Grant/award | 2350 | $0 |
| Lutz Marcos M | Director | 2026-04-28 | Grant/award | 2350 | $0 |
| Nayyar Nayaki R | Director | 2026-04-28 | Grant/award | 2350 | $0 |
| PAGE GREGORY R | Director | 2026-04-28 | Grant/award | 3870 | $0 |
| Policinski Christopher J. | Director | 2026-04-28 | Grant/award | 2350 | $0 |
| Preete Kerry J | Director | 2026-04-28 | Grant/award | 2350 | $0 |
| Ward Pat | Director | 2026-04-28 | Grant/award | 2350 | $0 |
| Eathington Samuel R | See Remarks | 2026-02-28 | Tax withholding | 471 | $38K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Corteva's risk profile deteriorated materially this year, driven primarily by the newly disclosed spin-off of the company into two independent public companies — a complex, execution-heavy transaction carrying strategic, financial, tax, and operational risks including potential credit rating downgrade and loss of synergies. Worsening is broad-based, spanning regulatory (EPA/USDA/FDA funding cuts, antitrust task forces, climate rules), trade policy, cybersecurity/IP, and a 169% surge in indemnification assets signaling escalated environmental and litigation exposure. Two meaningful easings — remediation of a material internal control weakness and removal of the DuPont tax indemnification dispute — partially offset the picture but do not alter the dominant worsening trend.
6 company-specific · 2 eased/removed · 2 common-mode
Newly disclosed major strategic transaction (spin-off into two public companies) with execution risk, timeline uncertainty, and potential failure to achieve intended benefits.
Risks related to our Proposed Separation Corteva is subject to risks related to its plans to separate its seed and crop protection businesses in a spin-off that will result in two standalone public…
Newly disclosed proposed separation of Corteva into two independent public companies. Material strategic, operational, financial, and tax risks including management distraction, potential credit rating downgrade, loss of synergies, and potential tax liability if spin-off fails qualification test.
Part I ITEM 1A. RISK FACTORS, continued including, among others, the filing and effectiveness of a Form 10 registration statement with the SEC, receipt of a tax opinion from external counsel to the…
New disclosure of material regulatory risk: EPA, USDA, FDA funding/staff cuts could delay product approvals and commercialization, directly impacting biotech and pesticide product timelines and IP value.
Recent funding and staff reductions, including at the EPA, the USDA, the FDA and the U.S. Department of Health and Human Services ("HHS"), could hinder our ability to receive timely regulatory…
New Trump executive order (Dec 2025) escalates antitrust scrutiny with dedicated Food Supply Chain Security Task Forces specifically targeting seeds sector and foreign control concerns, intensifying regulatory risk.
Corteva’s business is subject to various competition and antitrust, rules and regulations around the world, and as the size of its business grows, scrutiny of its business by legislators and…
Indemnification assets increased 169% ($513M to $975M), signaling escalated environmental and litigation liabilities. Material quantitative change in contingent recovery exposure.
Part I ITEM 1A. RISK FACTORS, continued glyphosate containing weedkiller products has resulted in negative publicity and sentiment and may lead to similar suits with respect to glyphosate-containing…
New disclosure of IP vulnerability to cybersecurity incidents, employee error, theft, and counterfeit products—substantive operational and security risks not previously disclosed.
Part I ITEM 1A. RISK FACTORS, continued Corteva has designed and implemented internal controls to restrict use of, access to and distribution of its intellectual property. Despite these precautions…
Material weakness in internal controls over financial reporting was disclosed and remediated. Removal signals successful remediation and restoration of control effectiveness.
EIDP has identified a material weakness in its internal control over financial reporting, which could negatively impact the accurate and timely reporting of its results of operations and financial…
Material dispute with DuPont over tax indemnification and separation agreement liabilities removed. Suggests resolution or favorable outcome reducing contingent liability risk.
DuPont is currently disputing with Corteva certain provisions of the Separation Agreement and Tax Matters Agreement. As discussed further in Note 16 - Commitments and Contingent Liabilities, to the…
Added explicit disclosure of climate-change regulatory risk, timing/enforcement uncertainty, and potential for costs exceeding accruals—escalating regulatory exposure.
The costs of complying with evolving regulatory requirements could negatively impact Corteva’s business, results of operations and financial condition. Actual or alleged violations of environmental…
Added explicit trade retaliation risk (countries purchasing less from US) and new manufacturing cost/customer demand impacts from policy changes. Escalates trade policy risk beyond prior year's Trump administration reference.
Corteva’s operations outside the United States are subject to risks and restrictions, which could negatively affect Corteva’s business, results of operations and financial condition. Corteva’s…
Corteva announced consolidated financial results for Q2 and first half 2026 on July 30, 2026, with a press release and financial statement schedules furnished as exhibits. The disclosure includes net sales of $6.38B (Q2) and $11.28B (1H), income from continuing operations, EPS, and updated full-year 2026 guidance raising Operating EBITDA to $4.1-$4.3B and Operating EPS to $3.60-$3.80 per share. This is a standard quarterly earnings release with material financial results and forward guidance.
View raw filing on EDGAR →Karen Grimes, Marcos Lutz, Charles Magro, and Kerry Preete resigned from Corteva's board of directors effective immediately prior to the spin-off consummation, representing a significant change in board composition for the parent company in connection with the planned separation.
View raw filing on EDGAR →Corteva announced the post-separation boards of directors for Corteva and Vylor in connection with its planned separation of its seed business into an independent public company, scheduled for 4Q 2026, constituting a material disposition of a business segment.
View raw filing on EDGAR →